Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Paradigm4, an integrated scientific data analytics company, has launched flexFS, its elastic cloud file system for flexible and more resource-efficient data storage and scalable computing.
Marilyn Matz, Chief Executive Officer and Co-Founder, Paradigm4 “Genomics’ role in the life science vision “is only as credible as its implementation,”
Dr. Zach Pitluk and Dr. Srikant Sarangi on preparing the way for AI/ML to impact drug discovery and development.
